Current Month 2013
Article Features
  Analysis Shows Increased Use of Hypofractionated Whole
Common Chemotherapy Is Not Heart Toxic in Patients with BRCA1/2 Mutations
Common Polymorphism in DNA Can Lead to Tumor Progression
Early Trial of New Drug Shows Promise for Patients with Triple-Negative Breast Cancer
Genotyping Errors Plague CYP2D6 Testing for Tamoxifen Therapy
Herceptin Found to Improve Long-Term Survival of HER2-Positive Breast Cancer Patients
Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer
Male and Female Breast Cancers Are Not Identical
Metal Test Could Help Diagnose Breast Cancer Early
Microwave Imaging of the Breast May Provide Better and Cheaper Images for Cancer Screening
Migraine Is Not Associated with Breast Cancer Risk
Most Women with Early-Stage Breast Cancer Receive Radiation for Too Long
New Drug Combination for Advanced Breast Cancer Delays Disease Progression
New Studies Target Androgen in Breast Cancer
Novel Approach for Estrogen-Positive Breast Cancer Reported
Pre-Surgery Chemotherapy Benefits for Triple-Negative Breast Cancer
Proteins Drive Cancer Cells to Change States
Researchers Confirm Whole-Genome Sequencing Can Successfully Identify Cancer-Related Mutations
Researchers Map Paths to Cancer Drug Resistance
Risk for Leukemia After Treatment for Early-Stage Breast Cancer Higher Than Reported
Study Shows How Breast Cancer Cells Break Free to Spread in the Body
Study Shows Superior Activity for Nab-Paclitaxel vs Paclitxel in Early Breast Cancer
Suppressing a Protein Reduces Cancer Spread in Mice
Women with Dense Breasts Will Have to Look Beyond Ultrasound for Useful Supplemental Breast Cancer Screening


New Drug Combination for Advanced Breast Cancer Delays Disease Progression
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study were presented at the 2014 San Antonio Breast Cancer Symposium by Dr. Kerin Adelson, assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven.

The trial enrolled 118 post-menopausal women with metastatic hormone-receptor-positive breast cancer whose cancer continued to progress after being treated with an aromatase inhibitor. The study, based on work done by Doris Germain of Mt. Sinai Hospital, found that the combination of the drugs bortezomib and fulvestrant versus fulvestrant alone doubled the rate of survival at 12 months and reduced the chance of cancer progression overall.

Bortezomib, used most commonly in treating multiple myeloma, is a proteasome inhibitor that prevents cancer cells from clearing toxic material. Fulvestrant causes clumping of the estrogen-receptor protein. When bortezomib blocks the ability of the cell to clear these protein clumps, they grow larger and become toxic to the cancer cells. This, in turn, amplifies the effectiveness of fulvestrant, a drug commonly used in this subset of patients.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon